Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neuren Lifts Income Guidance as DAYBUE Sales Rise and German Launch Triggers Milestone

NEU: $23.24 +17.49% · MC: $2.9B

Neuren Pharmaceuticals raised its annual trofinetide income guidance to US$91 million–US$93 million from US$53 million–US$56 million, including a US$35 million milestone earned from the drug’s German launch. Partner Acadia reported quarterly DAYBUE sales rose 39% from a year earlier to US$140 million, while Neuren’s royalties rose 51% to US$16 million. Acadia also raised its annual global sales guidance and plans a Japanese regulatory filing next year, with a potential launch the following year subject to approval.

Source announcements: 2026-11-05 09:57 to 2026-11-05 09:57 Sydney time
Story updated 2026-11-05 10:37 Sydney time
SourcesQ3 2026 DAYBUE net sales up 39%, full year guidance upgraded
Comments